disease-specific patient-reported outcome measure. This patient-reported outcome measure is designed to capture the overall disease burden associated with CMT. The CMTHI and its subscales are designed to be used in therapeutic trials, based on written guidance from the FDA. 9 Here, we detail the construction of the instrument, including its content validation, test-retest reliability, and ability to discriminate between groups thought to have different disease burden.
Patients and Methods

Eligibility Criteria
Participants were aged > 18 years and had a diagnosis of any form of CMT by genetic or clinical criteria. 10 Participants were recruited from the Inherited Neuropathies Consortium Rare Diseases Clinical Research Network (RDCRN; 1U54NS0657) Contact Registry for Group 1. Groups 2 and 3 were recruited from Investigator clinics (Utah, Rochester, and Iowa) and enrolled at either University of Utah (Group 2) or University of Rochester (Group 3). Three different samples were utilized for different aspects of this research. The first group (Group 1, n = 407) comprises those participants who initially completed the survey, as reported. 8 The second group (Group 2, n = 15) comprises those participants who completed the cognitive interviews. The final group (Group 3, n = 45) comprises those participants who performed repeat assessments for the evaluation of test-retest reliability. All research activities were approved by the institutional review boards at the University of Rochester and the University of Utah. All participants provided informed consent.
CMTHI Creation
Question Selection and Content Validity. We have previously reported on qualitative interviews that were used to comprehensively identify the symptom burden of CMT. 7 These 214 symptoms were then included on a questionnaire that was given to 407 participants so that they could rate the impact of each symptom on a 6-point Likert scale, as previously reported. 8 A population impact score was assigned to each question based on its prevalence in the individuals responding to the survey and relative impact (scale ranges 0-4 with 4 representing the highest level of burden). 8 To create the initial CMTHI, we utilized questions with a population impact score > 0.5. CMTHI questions that met this criterion were excluded if there was consensus among investigators that the question (1) was redundant, (2) was not amenable to therapeutic intervention, or (3) had vague wording.
Factor Analysis. The initial survey grouped questions into content-similar subscales. We subsequently used exploratory factor analysis to determine whether questions within each subscale measured a similar concept. The exploratory factor analysis was performed using SPSS (IBM, Armonk, NY), with principal axis factoring as the extraction method and oblimin with Kaiser normalization as the rotation method. The response data from Group 1 were used for this analysis. Questions with factor loadings > 0.30 were determined to load on a particular factor. Questions with cross-loadings on different factors and those with factor loadings < 0.30 on the primary factor were considered for transfer, depending on content, to a more appropriate subscale. Cronbach alpha was used to evaluate the internal consistency of the whole scale. Additional questions were removed if there was low internal consistency within a factor. Confirmatory factor analysis was performed using MPlus 7.4 (Muthén & Muthén, Los Angeles, CA) to determine factor validity of the subscales. Estimation of parameters was carried out using weighted least squares with mean and variance adjustment with delta parameterization over polychoric correlations. This method is robust to item skewness and kurtosis.
Cognitive Interviews. Once the exploratory factor analysis was complete, we arranged questions in the CMTHI by subscale. This questionnaire represented version 1 of the CMTHI. Semistructured interviews were then performed with 15 participants with CMT (Group 2). These interviews assessed the overall comprehension of the instrument, feasibility of use, scoring, and period of time by which participants assessed the symptom severity. Participants were provided version 1 of the CMTHI and asked to complete it. Following completion, participants described the theme behind each subscale, assessed whether the provided Likert responses accurately depicted their choices, provided feedback on wording, and identified symptoms that were not assessed. They also provided an assessment of the timeframe they used to recall the individual symptom. These interviews were recorded and analyzed. CMTHI questions were discarded or reworded based on participant input to create version 2 of the instrument.
Test-Retest Reliability
Test-retest reliability of the CMTHI version 2 was assessed in 45 participants with CMT (Group 3). Participants were provided the survey online, along with the SF-36. Participants completed the initial survey and received the exact same survey 4 weeks later. Reliability was assessed using the total score across the entire instrument, each subscale score, and individual question Likert responses. Intraclass correlation coefficients (ICCs) were used to quantify the reliability of the instrument. Questions with an ICC < 0.70 were discarded. Once unreliable items were discarded, we performed another confirmatory factor analysis to confirm the continued construct validity of the instrument.
Scoring of the CMTHI
The overall instrument is weighted, with a possible score ranging between 0 and 100. Individual question weights were derived from the mean Likert response of each symptom using the survey responses from Group 1. The weighted sum of responses was transformed to a 0-100 scale by expressing it as a percentage of the maximum possible value, with a score of 100 representing the most severe disease burden and a score of zero representing no disease burden. A similar algorithm was developed to compute individual scores (range = 0-100) for each subscale.
Known Group Validity
The average CMTHI total score and subscale scores were determined for predefined subgroups that may have different disease severity. Groups were defined by employment (employed vs unemployed), disease duration (≥20 years vs < 20 years), and CMT subtype. Data from Group 1 were used for this analysis. Questions added after the original survey were treated as missing data. Group comparisons of the mean total scores were performed using Wilcoxon rank sum scores. To assess convergent validity, participants in Group 3 were provided the SF-36 at the same time as the CMTHI. The total CMTHI score was correlated with SF-36 scale scores using Pearson correlations. In addition, participants in Group 3 were evaluated using the CharcotMarie-Tooth Examination Score (CMTES), a validated impairment assessment of the symptoms and signs associated with CMT. 11 Participants were grouped into those whose CMTES was <10 and those whose CMTES was >10, to differentiate those individuals with less or more disability, respectively. A Wilcoxon rank sum test was used to compare the CMTHI scores between these groups. The mobility-Disability Severity Index (mDSI) is a 5-point scale (0-4) that assesses the disability associated with CMT.
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Participants scoring between 0 and 2 on the mDSI have no to mild disability, whereas those participants scoring 3 to 4 on the mDSI have moderate to severe disability. A Wilcoxon rank sum test was used to compare the CMTHI scores between these groups.
Results
Patients
The demographic and clinical characteristics for participants in Groups 1 to 3 are provided in Table 1. 8
Initial Question Selection
The initial survey included 214 symptoms in 20 themes. We eliminated 58 questions based on low impact (n = 17), redundancy (n = 18), lack of perceived responsiveness to intervention (n = 14), potential abrasiveness to respondents (n = 1), and vague wording (n = 8; Fig 1) .
Factor Analysis
The initial survey results from Group 1 were used for exploratory factor analysis. Eighteen different factors were identified from the exploratory analysis. As a result of the initial factor analysis, 43 questions were removed as they had low internal consistency within a factor (Cronbach alpha < 0.40; see Fig 1) . Eight questions were moved to achieve a better internal consistency with the subscale. Finally, 5 subscales were removed because they had an overall low internal consistency or the questions were moved to another subscale to reduce the burden of the test. For example, the subscale "Decreased Satisfaction in Social Situations" was merged with "Decreased Performance in Social Situations." Four questions formed new single-item subscales (eg, "Breathing Problems") because they had low internal consistency within other factors but remained relevant questions to understand the burden of CMT on a patient. CMT = Charcot-Marie-Tooth disease; F = female; SD = standard deviation.
The instrument was subjected to a confirmatory factor analysis at the completion of patient interviews and test-retest reliability assessment. The internal consistency of each subscale is provided in Table 2 .
Patient Assessment with Qualitative Interviews
Fifteen patients with CMT of different ages and subtypes provided feedback regarding the ease of completion and clarity of the instrument (Group 2). All participants were asked to identify the theme represented by each subscale, and all provided correct responses. Three questions were removed because participants could not understand what the question was asking (see Fig 1) . Participants provided disparate interpretations of the questions on "visual spatial difficulties," "difficulty doing laundry," and "sense that walking is uneven."
Overall, the participants provided positive feedback about the instructions, ease of use, and whether the CMTHI accurately captured all of the symptoms that may result from CMT. On average, the instrument required 15 minutes to complete (range = 5-25 minutes).
Test-Retest Reliability
Forty-five participants (Group 3) completed the CMTHI twice over a 1-month period ( Supplementary Fig). The scores ranged from 0 to 95.88. Five questions were eliminated for an ICC < 0.70 (see Fig 1) . The remainder of the questions had a test-retest reliability higher than this standard threshold. 13 The 5 questions were: "difficulty running" (ICC = 0.55), "having to look at feet when walking" (ICC = 0.65), "frustration" (ICC = 0.66), "impaired body image" (ICC = 0.68), and "impaired interaction with family members" (ICC = 0.64). Removal of these items yielded the final version of the CMTHI. The final version of the CMTHI consists of 18 subscales that measure 105 symptomatic themes of importance to patients with CMT. There are 127 total questions in the CMTHI. Participants respond to each question used a 6-point Likert scale to identify the current impact that each individual symptom has on their lives. The format of the questions and Likert scale has been previously tested and validated through extensive qualitative testing in multinational neuromuscular populations. [14] [15] [16] [17] The exact subscales measured using the CMTHI and the number of questions in each subscale are detailed in Table 2 . Table 2 lists the ICC values for the CMTHI total score and each subscale. A plot of the CMTHI total scores at the first versus second (repeat) assessments is provided in Figure 2 .
Known Group Validity and Concurrent Validity
The CMTHI total score and subscale scores were able to differentiate between groups with different disease burden ( Table 3; Supplementary Table) . Four theme questions were added to the final instrument that were not present in the initial survey (see Fig 1) . These were treated as missing data as part of this analysis. There were higher mean CMTHI total scores in patients who were not employed and had longer disease duration. Most of the subscales had a higher mean score in participants with a longer disease duration; the exceptions were for subscales that measured emotional issues, cognitive problems, and constipation. There were no significant differences in mean CMTHI subscale scores between different CMT types with the exception of mean numbness scores, which were higher in CMT1B and CMT4, and lower in CMTX. There were some differences between male and female participants. Mean shoulder or arm weakness, pain, fatigue, and constipation scores were all higher in women. Six participants completed study visits remotely, and therefore did not have a CMTES score. There were differences in the CMTHI total score between those who are less impaired on the CMTES score and those who are more impaired. There were also significant differences comparing the CMTHI total score between those with minimal and more severe disability (see Table 3 ). Finally, the CMTHI total score and subscale scores had good correlation with the SF-36 scores (Table 4) .
Discussion
The CMTHI is a disease-specific, patient-reported outcome measure designed for this broad category of inherited neuropathies. This instrument is specifically designed to capture the disease burden of these disorders in the context of a clinical trial.
These results highlight the disease burden associated with CMT and demonstrate that patient-perceived disease burden as measured by the CMTHI increases with disease duration and is strongly associated with the ability to work. The CMTHI was able to differentiate between different neurologic impairment and disability levels within CMT, as measured by the CMTES and mDSI. The CMTHI, as a disease-specific instrument, has advantages over generic instruments. Disease-specific instruments are able to focus on the questions most relevant to the disease population, excluding those questions that are less relevant. Disease-specific instruments have been shown to have a reduced burden on the participant and improved sensitivity to change in a clinical trial. [18] [19] [20] Disease states, such as CMT, prove a unique challenge, as there is heterogeneity between the different subtypes. The known group comparison demonstrated minimal variation in scores between the CMT subtypes assessed.
The FDA has provided specific guidance on the creation of patient-reported outcomes, such as this one. 2, 21 The creation of this instrument was extensively based directly on patient input. Patients identified the initial survey items de novo, and then subsequently validated the final set of items. The methodology described was designed to comply with the FDA's recommendations to demonstrate the reliability and validity of a patientreported outcome measure. The CMTHI provides a mechanism to estimate disease burden in clinical trials. We have shown that the CMTHI is reliable and has a diverse range of subscales that have been psychometrically validated and shown to be important to the CMT population.
There are some limitations to our approach. The instrument was constructed based on input from CMT patients. These patients were recruited based on their involvement with the Inherited Neuropathies Consortium RDCRN. Although we believe this to be an adequate representation of the CMT patients that may participate in future clinical trials, we cannot definitely state that this sample represents the greater CMT community. There were limited differences on the instrument when comparing CMT subtypes. It is possible that there was an insufficient sample size for rare CMT mutations to detect subtype differences. Six participants did not complete the CMTES, so it is possible that this analysis was skewed by severity. However, relationships between the CMTHI and CMTES were concordant with those observed between the CMTHI and mDSI, which was completed by all participants. In addition, the responsiveness of this instrument has yet to be determined. Although known groups testing is one way to crudely examine this, true responsiveness to disease progression must be confirmed using a longitudinal study.
These results describe the creation of the CMTHI, a disease-specific patient-reported outcome for use in CMT. The instrument is reliable and able to discriminate between different levels of disease burden. Although these results provide initial reliability and validity testing, the instrument will benefit from additional longitudinal study to define the sensitivity of the instrument prior to use in clinical trials.
